FZMD (Fuse Medical) Cyclically Adjusted Revenue per Share: $1.06 (As of Jun. 2023)


FZMD Fuse Medical Inc FZMD
12 GF Score
Price $0.03
View Full Analysis

What is Fuse Medical Cyclically Adjusted Revenue per Share?

Fuse Medical FZMD 12 Cyclically Adjusted Revenue per Share is $1.06 as of Jun. 2023. GuruFocus rates FZMD with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fuse Medical's adjusted revenue per share for the three months ended in Jun. 2023 was $0.064. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.06 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-12), Fuse Medical's current stock price is $0.02925. Fuse Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $1.06. Fuse Medical's Cyclically Adjusted PS Ratio of today is 0.03.


Fuse Medical  (OTCPK:FZMD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Fuse Medical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.02925/1.06
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fuse Medical Cyclically Adjusted Revenue per Share Related Terms


Fuse Medical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Fuse Medical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fuse Medical Cyclically Adjusted Revenue per Share Chart

Fuse Medical Annual Data
Trend Aug13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 1.24 1.13 1.10 1.07

Fuse Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 1.09 1.07 1.07 1.06

FZMD vs GTHP, SONX, PBIO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Fuse Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuse Medical Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fuse Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fuse Medical's Cyclically Adjusted PS Ratio falls into.


FZMD
12GF Score
Fuse Medical Inc FZMD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fuse Medical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fuse Medical's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.064/305.1090*305.1090
=0.064

Current CPI (Jun. 2023) = 305.1090.

Fuse Medical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201308 2.648 233.877 3.455
201311 0.000 233.069 0.000
201403 0.046 236.293 0.059
201406 0.072 238.343 0.092
201409 0.052 238.031 0.067
201412 0.077 234.812 0.100
201503 0.046 236.119 0.059
201506 0.083 238.638 0.106
201509 0.071 237.945 0.091
201512 0.070 236.525 0.090
201603 0.028 238.132 0.036
201606 0.018 241.018 0.023
201609 0.016 241.428 0.020
201612 1.589 241.432 2.008
201703 0.595 243.801 0.745
201706 0.518 244.955 0.645
201709 0.364 246.819 0.450
201712 0.265 246.524 0.328
201803 0.091 249.554 0.111
201806 0.087 251.989 0.105
201809 0.099 252.439 0.120
201812 0.110 251.233 0.134
201903 0.068 254.202 0.082
201906 0.072 256.143 0.086
201909 0.081 256.759 0.096
201912 0.104 256.974 0.123
202003 0.066 258.115 0.078
202006 0.057 257.797 0.067
202009 0.077 260.280 0.090
202012 0.100 260.474 0.117
202103 0.063 264.877 0.073
202106 0.081 271.696 0.091
202109 0.061 274.310 0.068
202112 0.083 278.802 0.091
202203 0.065 287.504 0.069
202206 0.066 296.311 0.068
202209 0.065 296.808 0.067
202212 0.066 296.797 0.068
202303 0.057 301.836 0.058
202306 0.064 305.109 0.064

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.06 mean?
Fuse Medical (FZMD) has a Cyclically Adjusted Revenue per Share of $1.06 as of Jun. 2023. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fuse Medical and its competitors.
Is Fuse Medical's Cyclically Adjusted Revenue per Share too high?
Fuse Medical's current Cyclically Adjusted Revenue per Share is $1.06. Overall, Fuse Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Fuse Medical's Cyclically Adjusted Revenue per Share compare to GTHP and SONX?
Fuse Medical's Cyclically Adjusted Revenue per Share of $1.06 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fuse Medical and its competitors. Fuse Medical's current Cyclically Adjusted Revenue per Share is $1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuse Medical stock overvalued right now?
Fuse Medical (FZMD) has a current Cyclically Adjusted Revenue per Share of $1.06. The current Cyclically Adjusted Revenue per Share is $1.06. Fuse Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Fuse Medical (FZMD), the current Cyclically Adjusted Revenue per Share is $1.06 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fuse Medical Business Description

Address 4343 Sigma Road, Suite 500, Farmers Branch, TX, USA, 75244
Fuse Medical Inc is a manufacturer, distributor, and wholesaler of medical device implants, offering portfolio of orthopedic implants and biologics including: internal fixation products, upper and lower extremity plating and total joint reconstruction implants, soft tissue fixation and augmentation for sports medicine procedures, spinal implants for trauma, degenerative disc disease and deformity indications, and osteo-biologics, regenerative and connective tissues, which include human allografts, substitute bone materials, tendons, and regenerative tissues. Its portfolio of Orthopedic Implants and Biologics provide products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers including hospitals, medical facilities, and sub-distributors.
12GF Score

Get the complete analysis for FZMD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price